1. What Is the Cardiac Biomarker Market?
The Cardiac Biomarker Market covers the laboratory tests and point-of-care assays that detect and quantify the protein and biochemical markers released into the bloodstream when cardiac muscle is damaged, ischaemic, or haemodynamically stressed. The markers include high-sensitivity cardiac troponin I and T for acute myocardial infarction diagnosis and BNP and NT-proBNP for heart failure diagnosis and monitoring. The myoglobin, CK-MB, and copeptin contribute to the continuously advancing multi-biomarker strategy that improves the diagnostic sensitivity and specificity of early AMI rule-out in emergency medicine. High-sensitivity troponin assays measuring cardiac troponin at concentrations below 5 nanograms per litre from leading manufacturers have enabled the 0-hour and 1-hour rule-out algorithms. The European Society of Cardiology recommends these algorithms for the rapid identification of the 80 to 90 percent of chest pain patients. The patients can safely be discharged without AMI within 1 to 2 hours of emergency department presentation. The cardiac biomarker market includes the automated immunoassay platforms that process the high volumes of troponin and BNP tests in hospital core laboratories. The market also includes the point-of-care troponin analysers in emergency department fast-track pathways. The research biomarker platforms identify the novel cardiac biomarkers including high-sensitivity CRP, soluble ST2, and galectin-3 that risk-stratify heart failure patients beyond the established natriuretic peptide tests. Acute coronary syndrome risk stratification in emergency medicine uses the hsTn 0-1-hour algorithm. The chronic heart failure monitoring uses serial NT-proBNP to guide the titration of heart failure therapies. The post-AMI risk stratification uses peak troponin for infarct size estimation, and these represent the primary cardiac biomarker clinical applications.
2. Cardiac Biomarker Market Size & Forecast
3. Emerging Technologies
- High-sensitivity troponin analytical precision with coefficient of variation below 10 percent below the 99th percentile upper reference limit is required by the GRACE and ESC 0-1 hour AMI algorithms. The Roche hsTnT, Abbott hsTnI, and Siemens hsTnI-Ultra assays on centralised immunoassay platforms have achieved this precision. The clinical validation enrolled over 30,000 patients across the BACC, TRAPID-AMI, and APACE studies. These studies established the algorithms that emergency cardiology guidelines now recommend.
- Copeptin serves as the early surrogate for the endogenous arginine vasopressin stress hormone that peaks within 30 to 60 minutes of myocardial ischaemia onset. The copeptin complements the troponin that peaks later. The dual-biomarker strategy of copeptin plus conventional troponin enables the 0-hour rule-out in chest pain patients with symptom onset less than 3 hours before emergency department presentation where troponin alone does not achieve adequate sensitivity.
- NT-proBNP age-adjusted rule-in and rule-out thresholds enable the emergency department stratification of acute dyspnoea patients into acute HF versus non-cardiac dyspnoea categories. The Januzzi three-zone age-stratified interpretation supports the ESC acute heart failure guidelines. The guidelines recommend NT-proBNP as the primary acute HF biomarker.
- Point-of-care high-sensitivity troponin testing uses the Abbott i-STAT TnI-Ultra and Abbott iStat CLIA-waived hsTnI assays achieving equivalent clinical performance to laboratory analyser troponin in emergency department fast-track pathways. The testing enables the direct bedside 0-hour rule-out without specimen transport to the central laboratory. The central laboratory transport and analysis time from peripheral specimen collection takes 30 to 60 minutes.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Clinical Chemistry Market.
4. Key Market Opportunity
A material opportunity in the Cardiac Biomarker market is POC high-sensitivity troponin expansion in emergency settings, where rapid bedside hs-troponin results enable immediate triage and reduce emergency overcrowding. Roche Diagnostics, Siemens Healthineers, and Abbott capture this POC cardiac troponin opportunity. A parallel growth driver is driven by multimarker cardiac risk panel development. As POC hs-troponin expands and multimarker panels advance, the addressable opportunity is expanding from core laboratory troponin toward POC rapid cardiac triage and comprehensive risk profiling.
5. Top Companies in the Cardiac Biomarker Market
The following organisations hold leading positions in the Cardiac Biomarker Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Roche
- Abbott
- Siemens Healthineers
- BioMerieux
- Danaher
- Quidel Ortho
- Thermo Fisher Scientific
- Randox Laboratories
6. Market Segmentation
The Cardiac Biomarker Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Biomarker | hs-TroponinBNPNT-proBNPCK-MBMyoglobinCopeptin |
| By Application | Acute MIHeart FailureRisk Stratification |
| By Setting | Core LabEmergency POC |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Cardiac Biomarker Market trajectory over the forecast period:
High-Sensitivity Troponin 0-1 Hour AMI Rule-Out Algorithms Validated in 30,000-Plus Patients Across BACC, TRAPID-AMI, and APACE Studies Have Replaced the 6-Hour Observation That Lower-Sensitivity Troponin Required in ESC Acute Coronary Syndrome Guidelines.Abbott's ARCHITECT STAT high-sensitivity troponin I, Roche's Elecsys high-sensitivity troponin T, and Siemens' TnI-Ultra assay represent the high-sensitivity troponin platforms that major hospital laboratories deploy for the 0-1-hour and 0-2-hour accelerated diagnostic protocols that ESC and AHA guidelines recommend for acute coronary syndrome evaluation. The high-sensitivity troponin assay has enabled the detection of myocardial injury at troponin concentrations below the 99th percentile of a healthy reference population, allowing rule-out of AMI in patients with normal troponin at presentation and 1-hour follow-up with sensitivity exceeding 99 percent for AMI in multiple validation cohorts. The point-of-care high-sensitivity troponin platforms from Abbott's i-STAT TNTG and Roche's CARDIAC Reader have extended rapid troponin testing to emergency settings where central laboratory turnaround time is a constraint for the time-critical AMI triage decisions that emergency physicians require.
Copeptin as the Early AVP Stress Hormone Surrogate Peaking Within 60 Minutes of Ischaemia Onset Is Enabling the 0-Hour Dual-Biomarker Rule-Out in Early-Presenting Chest Pain Patients Where Troponin Alone Cannot Achieve Adequate Sensitivity.Roche's Elecsys NT-proBNP and Abbott's ARCHITECT NT-proBNP assays provide the quantitative natriuretic peptide measurement that cardiologists and emergency physicians use for the diagnosis of acutely decompensated heart failure, monitoring of chronic heart failure treatment response, and risk stratification of dyspnoeic patients where heart failure and pulmonary or other causes of breathlessness must be distinguished. The ACC/AHA heart failure guideline incorporation of BNP and NT-proBNP as Class I recommendations for the evaluation of dyspnoea and for the risk stratification of patients with chronic heart failure has driven the adoption of natriuretic peptide testing in cardiology and emergency medicine practice. The point-of-care BNP testing from Biosite's Triage BNP and Alere's NT-proBNP system has extended natriuretic peptide testing to the emergency department and acute care setting where central laboratory testing would delay the results needed for admission and treatment decisions in acutely dyspnoeic patients.
Age-Adjusted NT-proBNP Thresholds Enabling Acute HF Rule-In and Rule-Out From Acute Dyspnoea Are Providing the Emergency Department Stratification That ESC Acute Heart Failure Guidelines Recommend as the Primary Biomarker for Acute HF Diagnosis.Siemens' Atellica IM system with multi-marker cardiac panel capability, Roche's cobas cardiac panel, and Abbott's ARCHITECT high-speed cardiac testing provide the analytical throughput and multi-marker capability that emergency departments and cardiac units use for simultaneous assessment of multiple biomarkers from a single sample aliquot. The emerging cardiac biomarker panel for high-sensitivity CRP, troponin, and NT-proBNP combined risk stratification has demonstrated additive predictive value for major cardiovascular events in primary prevention populations, supporting the use of multi-marker testing for cardiovascular risk stratification beyond the acute cardiac event diagnosis application. The galectin-3 and soluble ST2 cardiac fibrosis biomarkers that provide prognostic information about myocardial remodelling independent of natriuretic peptide levels represent the next generation of heart failure biomarkers that are being incorporated into clinical practice alongside established natriuretic peptide testing.
For related market intelligence, see the In Vitro Diagnostics Market.
8. Segmental Analysis
By biomarker, the high-sensitivity cardiac troponin segment dominated the Cardiac Biomarker Market in 2025, as Roche Elecsys hsTnT and Abbott ARCHITECT hs-cTnI anchored rule-in and rule-out algorithms for acute myocardial infarction diagnosis, generating the dominant share of cardiac biomarker assay revenue.
By setting, the point-of-care and emergency department segment is projected to register the highest growth rate through 2034, as Abbott Alinity i and Beckman Coulter DxI 9000 portable immunoassay systems extend high-sensitivity troponin testing from central-laboratory to emergency-department platforms where 0-hour and 1-hour algorithms accelerate chest-pain patient disposition.
9. Regional Analysis
Regional demand patterns across the Cardiac Biomarker Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Cardiac Biomarker Market in 2025, accounting for approximately 46% of global revenue, due to US premium pricing for high-sensitivity troponin assays and the large emergency department acute MI evaluation volume. Moreover, hs-troponin rapid rule-out protocol adoption is most advanced in the US. In addition, NT-proBNP heart failure monitoring is established. Regional dominance is attributed to this combination of pricing environment and rapid protocol adoption.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Cardiac Biomarker Market through 2034, driven by the very large cardiovascular disease burden in China, Japan, and South Korea and the growing emergency department infrastructure. The region is also witnessing hs-troponin rapid protocol adoption growing. Moreover, NT-proBNP heart failure monitoring is expanding. The combination of these demand drivers and cardiovascular burden positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Cardiac Biomarker Market was valued at USD 4.14 Bn in 2025 and is projected to reach USD 9.60 Bn by 2034, growing at a CAGR of 9.8% over the 2026–2034 forecast period.
The Cardiac Biomarker Market is projected to grow at a CAGR of 9.8% from 2026 to 2034.
North America dominated the Cardiac Biomarker Market in 2025, accounting for approximately 46% of global revenue, due to US premium pricing for high-sensitivity troponin assays and the large emergency department acute MI evaluation volume.
The leading companies in the Cardiac Biomarker Market include Roche, Abbott, Siemens Healthineers, BioMerieux, Danaher, Quidel Ortho, Thermo Fisher Scientific, Randox Laboratories.
High-sensitivity troponin 0-1 hour ami rule-out algorithms validated in 30,000-plus patients across bacc, trapid-ami, and apace studies have replaced the 6-hour observation that lower-sensitivity troponin required in esc acute coronary syndrome guidelines.
By biomarker, the high-sensitivity cardiac troponin segment dominated the Cardiac Biomarker Market in 2025, as Roche Elecsys hsTnT and Abbott ARCHITECT hs-cTnI anchored rule-in and rule-out algorithms for acute myocardial infarction diagnosis, generating the dominant share of cardiac biomarker assay revenue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.